公开(公告)号：US20240254242A1

公开(公告)日：2024-08-01

申请号：US18604851

申请日：2024-03-14

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kyung Moo YEA ,  Beom Yong LEE ,  Jong Won JEONG

IPC: C07K16/28 ,  A61K39/00 ,  A61P3/00

CPC classification number: C07K16/2863 ,  A61P3/00 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622

Abstract: The present invention relates to a GFRAL-antagonistic antibody having improved affinity and a use thereof, and more particularly, the present invention relates to an anti-GFRAL antibody having improved affinity, comprising a heavy chain CDR and a light chain CDR of specific sequences, or an antigen-binding fragment thereof. The anti-GFRAL antibody having improved affinity exhibits higher binding ability to a GFRAL protein than a conventional anti-GFRAL antibody, and thus is expected to be effectively used for improving or treating cancer-related anorexia or cachexia syndrome and side effects of chemotherapy anticancer drugs.

公开(公告)号：US20230295307A1

公开(公告)日：2023-09-21

申请号：US17928979

申请日：2021-06-02

Applicant: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kyung Moo YEA ,  Beom Yong LEE ,  Jong Won JEONG

IPC: C07K16/28 ,  A61P43/00

CPC classification number: C07K16/2863 ,  A61P43/00 ,  C07K2317/565

Abstract: The present invention relates to a GFRAL-antagonistic antibody and a use thereof, and more particularly, to an anti-GFRAL antibody comprising a heavy chain CDR and a light chain CDR of specific sequences, and an antigen-binding fragment thereof. The anti-GFRAL antibody is expected to be usefully utilized for ameliorating or treating anorexia-cachexia syndrome associated with cancer, and adverse effects of chemotherapeutic drugs.